0
Signs and Symptoms of Chest Diseases |

Efficacy of Levodropropizine: 2 Meta-analyses in Pediatric and Adult Population

Francesco De Blasio, MD; Luigi Lanata, MD; Peter Dicpinigaitis, MD; Federico Saibene, MD; Michela Bagnasco, PhD; Alessandro Zanasi, MD; Giovanni Fontana, MD
Author and Funding Information

Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center, Private Hospital, Naples, Italy


Chest. 2014;145(3_MeetingAbstracts):565A. doi:10.1378/chest.1836465
Text Size: A A A
Published online

Abstract

SESSION TITLE: Symptoms of Respiratory Disease Posters

SESSION TYPE: Poster Presentations

PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM

PURPOSE: Cough is a very common symptom and may have a deep impact on quality of life both of children and adults, thus often requiring an empiric treatment with antitussive agents. Levodropropizine is a very well tolerated peripheral drug, while central cough suppressants (opioids and non opioids) may be associated with side effects that limit their use, especially in children. The aim of our two meta-analysis is to evaluate the overall comparative efficacy of levodropropizine in both pediatric and adult population.

METHODS: After comprehensive systematic literature search on main electronic databases (PubMed/MEDLINE, EMBASE, and Cochrane Library), we performed a first standardized meta-analysis of 4 controlled clinical studies of levodropropizine (3 vs. central antitussives and 1 vs. placebo) assessing efficacy cough outcomes, including a total of 780 children. We also performed a meta-analysis of 7 controlled clinical studies of Levodropropizine (5 vs. central antitussives and 2 vs. placebo) including 2633 patients, both children and adults. Main efficacy parameters were cough frequency, severity, and night awakenings.

RESULTS: The first meta-analysis of all standardized efficacy parameters, only in pediatric patients, showed a highly statistically significant difference in the overall antitussive efficacy in favor of Levodropropizine vs. control treatments (p = 0.001). The heterogeneity test for the efficacy outcome was not statistically significant (p=0.0619). Our second meta-analysis also showed a highly statistically significant difference in the overall antitussive efficacy in favor of levodropropizine vs. control treatments (p = 0.0044). The heterogeneity test for the efficacy outcome was not statistically significant (p=0.0856).

CONCLUSIONS: Our two meta-analysis indicate that Levodropropizine is an effective antitussive drug both in adults and children, with statistically significant better overall efficacy outcomes vs. central antitussives, in terms of reducing cough intensity, frequency and nocturnal awakenings.

CLINICAL IMPLICATIONS: These results further reinforce the favorable benefit/risk profile of Levodropropizine in the management of cough in pediatric and adult settings.

DISCLOSURE: Luigi Lanata: Employee: Medical Director Federico Saibene: Employee: Junior Medical Manager Michela Bagnasco: Employee: Medical Manager The following authors have nothing to disclose: Francesco De Blasio, Peter Dicpinigaitis, Alessandro Zanasi, Giovanni Fontana

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Topics

pediatrics

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Sport climbing: medical considerations for this new Olympic discipline. Br J Sports Med Published online Nov 7, 2016;
Giant Cell Fibroma in a Two-Year-Old Child. Case Rep Dent 2016;2016():7058356.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543